65,437 trials
Recurrent Skin Cancer · Squamous Cell Carcinoma of the Skin · Stage 0 Chronic Lymphocytic Leukemia
Primary: Objective Response Rate (Complete Response and Partial Response) — 0; 0 percentage of patients
Hepatitis C
Primary: Intrahepatic and Plasma HCV Viral Kinetics — 6.5; 4.9; 3.2; 4.2 log transformed copies/ml
Dyspnea · Pulmonary Complications · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Dyspnea as Measured by Oxygen Cost Diagram (OCD) — 8.98; 9.32 units on a scale — p=0.080
Aphakia · Cataract
Primary: Visual Acuity — 121; 121 subjects
Childhood Extracranial Germ Cell Tumor · Childhood Extragonadal Malignant Germ Cell Tumor · Childhood Malignant Ovarian Germ Cell Tumor
Primary: Response Rate as Measured by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria — 12; 8 participants
Pulmonary Arterial Hypertension
Primary: Left Ventricular End Diastolic Volume — 81; 70 ml
Infertility · Endometriosis
Primary: Number of Metaphase II Cells (MII) — 8.2; 8.2 MII cells
Focus of Study = Medical Writing
Primary: The Primary Outcome Will be the Average Score for Completeness of Reporting on a Scale of 0-10. — 7.1; 5.0 units on a scale — p=<0.001
Atherosclerosis · Coronary Artery Disease
Primary: Cardiac Death or Myocardial Infarction (CD/MI) — 2.2 percentage of paricipants
Chronic Pain
Primary: Change in Back Pain Intensity — 20.9; 25.6 Percent Change From Baseline — p=0.74
Osteoarthritis · Pain
Primary: Fatigue- Brief Fatigue Inventory (BFI) — 3.06; 3.18; 2.70 units on a scale
Recurrent Pterygium
Primary: Recurrence — 46; 34; 0; 3 eyes — p=<0.05
Posttraumatic Stress Disorder (PTSD)
Primary: Obtain Competitive Employment — 12; 32 participants — p=<0.001
Squamous Cell Carcinoma
Primary: Response Rate — .35; .22 proportion of participants
Rheumatoid Arthritis
Primary: Number of Participants Reporting Adverse Events (AEs) — 11; 7 number of participants